Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of AZD9291 on Rosuvastatin PK in EGFRm+ NSCLC
NCT02317016Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoints: Maximum Plasma Concentration for Rosuvastatin at Day 32 and Area Under the Curve from Time Zero to Infinity for Rosuvastatin at Day 32. Started Mar 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02317016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02317016.